Equity Profile

SRRK

Scholar Rock Holding Corporation

Health CareBiotechnology$6.5B

Aug6Thu

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

Scholar Rock Holding Corporation is a biotechnology company focused on developing innovative therapies for serious diseases. Operating in the health care sector, it aims to address unmet medical needs through its proprietary drug development platform.

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability and financial health, which investors closely monitor.

-0.82

Revenue

Revenue figures provide insight into the company's market performance and ability to generate sales, especially important for a biotech firm.

$0M

Wall Street expectations, options signals, track record, and call prep available with Pro.

SRRK Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

13%

Avg EPS Surprise

-11.44%

Avg Stock Reaction

+0.88%

Last Quarter Recap

In the last quarter, Scholar Rock reported an EPS of -0.83, slightly missing the consensus estimate of -0.82. The stock experienced a minor decline of 1.40% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts expect Scholar Rock to report a loss of $0.82 per share with no revenue, reflecting ongoing challenges in generating sales.

Bull Case

If the company can show progress in its drug development pipeline or unexpected revenue, it could lead to a positive market reaction.

Bear Case

Continued losses and lack of revenue could raise concerns about the company's viability and future funding needs.

Key Metrics to Watch

EPS

-0.82

Earnings per share is a key indicator of profitability and financial health, which investors closely monitor.

Revenue

$0M

Revenue figures provide insight into the company's market performance and ability to generate sales, especially important for a biotech firm.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will the company provide any updates on its drug development pipeline?

Investors are keen to understand progress in drug trials, which could impact future revenue potential.

What are the expectations for revenue generation in the upcoming quarters?

Clear guidance on revenue could help alleviate concerns about the company's financial stability.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for unexpected developments in the drug pipeline, which could lead to revenue sooner than anticipated.

Supporting Evidence

The options market is pricing a 13.4% move, indicating significant uncertainty that may not align with the current consensus.

Past earnings reactions show that even minor surprises can lead to significant stock movements.

Key Risk

If the company announces any positive developments in its drug trials, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's results are pivotal as they may indicate whether the company can stabilize its financial performance.

Bull Confirmed If

A narrower EPS loss of -0.66 or better would signal stronger-than-expected performance.

Bear Confirmed If

An EPS loss greater than -0.94 would confirm ongoing challenges in the business.

Pre-Earnings Positioning

Options Market

Implied Move

±13.4%

Historical Avg

±5.7%

Pricing rich

The options market is pricing in a significant move following the earnings report, indicating uncertainty about the results.

Options are pricing ±13.4% while SRRK has averaged ±5.7% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.7%

30d HV

36.3%

Calls (38K)P/C Ratio: 0.08Puts (6K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Scholar Rock beats expectations with a narrower EPS loss, history suggests a potential stock increase of around 1.15% on the following day.

In-Line / Cautious

If results are in line with expectations, the stock may react cautiously, reflecting uncertainty about future growth.

Miss

If the company misses expectations, history suggests a potential decline of about 1.15% on the next trading day.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the drug development pipeline and any potential partnerships.
2Any commentary on expected revenue generation in the next quarter.
3Insights into the company's funding strategy and financial health.
4Management's outlook on market conditions and competitive landscape.
5Details on any upcoming clinical trial results.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug3

ONBMO

ON Semiconductor Corporation

PreviewView

Aug3

LBMO

Company Snapshot

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability and financial health, which investors closely monitor.

-0.82

Revenue

Revenue figures provide insight into the company's market performance and ability to generate sales, especially important for a biotech firm.

$0M

Wall Street expectations, options signals, track record, and call prep available with Pro.

SRRK Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

13%

Avg EPS Surprise

-11.44%

Avg Stock Reaction

+0.88%

Last Quarter Recap

In the last quarter, Scholar Rock reported an EPS of -0.83, slightly missing the consensus estimate of -0.82. The stock experienced a minor decline of 1.40% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts expect Scholar Rock to report a loss of $0.82 per share with no revenue, reflecting ongoing challenges in generating sales.

Bull Case

If the company can show progress in its drug development pipeline or unexpected revenue, it could lead to a positive market reaction.

Bear Case

Continued losses and lack of revenue could raise concerns about the company's viability and future funding needs.

Key Metrics to Watch

EPS

-0.82

Earnings per share is a key indicator of profitability and financial health, which investors closely monitor.

Revenue

$0M

Revenue figures provide insight into the company's market performance and ability to generate sales, especially important for a biotech firm.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will the company provide any updates on its drug development pipeline?

Investors are keen to understand progress in drug trials, which could impact future revenue potential.

What are the expectations for revenue generation in the upcoming quarters?

Clear guidance on revenue could help alleviate concerns about the company's financial stability.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for unexpected developments in the drug pipeline, which could lead to revenue sooner than anticipated.

Supporting Evidence

The options market is pricing a 13.4% move, indicating significant uncertainty that may not align with the current consensus.

Past earnings reactions show that even minor surprises can lead to significant stock movements.

Key Risk

If the company announces any positive developments in its drug trials, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's results are pivotal as they may indicate whether the company can stabilize its financial performance.

Bull Confirmed If

A narrower EPS loss of -0.66 or better would signal stronger-than-expected performance.

Bear Confirmed If

An EPS loss greater than -0.94 would confirm ongoing challenges in the business.

Pre-Earnings Positioning

Options Market

Implied Move

±13.4%

Historical Avg

±5.7%

Pricing rich

The options market is pricing in a significant move following the earnings report, indicating uncertainty about the results.

Options are pricing ±13.4% while SRRK has averaged ±5.7% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.7%

30d HV

36.3%

Calls (38K)P/C Ratio: 0.08Puts (6K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Scholar Rock beats expectations with a narrower EPS loss, history suggests a potential stock increase of around 1.15% on the following day.

In-Line / Cautious

If results are in line with expectations, the stock may react cautiously, reflecting uncertainty about future growth.

Miss

If the company misses expectations, history suggests a potential decline of about 1.15% on the next trading day.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the drug development pipeline and any potential partnerships.
2Any commentary on expected revenue generation in the next quarter.
3Insights into the company's funding strategy and financial health.
4Management's outlook on market conditions and competitive landscape.
5Details on any upcoming clinical trial results.